SMAD2 and Bloom syndrome: Consistently, the key downstream signaling component, P‐smad2/3 in the TGF‐β pathway was also activated time‐dependently in BLM treated WT mice, and its level was further enhanced in BLM treated IL‐22R−/‐ mice (Figure 3G–H).